A joint 7-year cohort study of 2039 patients in Singapore and New Zealand found that heart failure patients with preserved ejection fraction (HFpEF) have better survival rates and outcomes compared to those with reduced ejection fraction (HFrEF). The study provides greater accuracy about the risk of dying from heart failure.
A group of molecules called chondroitin sulfate accumulates and causes inflammation in the hearts of patients with heart failure, leading to multi-organ failure. Researchers found that targeting these molecular nets may bring a fresh new treatment approach for patients with severe debilitating disease.
Scientists identify a novel RNA molecule, Singheart, which regulates genes controlling heart cell repair. This discovery may lead to new treatments for heart failure and could potentially heal the heart like skin wounds.